%0 Generic %A S., Aherfi %A O., Glazunova %A P., Borentain %A D., Botta-Fridlund %A L., Chiche %A S., Bregigeon %A A., Motte %A C., Tamalet %A P., Colson %D 2017 %T Supplementary Material for: Hepatitis C Virus of Subtype 2l in Marseille, Southeastern France %U https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Hepatitis_C_Virus_of_Subtype_2l_in_Marseille_Southeastern_France/4560790 %R 10.6084/m9.figshare.4560790.v1 %2 https://karger.figshare.com/ndownloader/files/7389856 %2 https://karger.figshare.com/ndownloader/files/7389862 %2 https://karger.figshare.com/ndownloader/files/7389859 %2 https://karger.figshare.com/ndownloader/files/7389865 %K Hepatitis C virus %K Genotype %K Subtype 2l %K Treatment %K Polymerase %X

The rate of eradication of chronic hepatitis C considerably increases with direct-acting antiviral agents, particularly hepatitis C virus (HCV) polymerase inhibitors. While implementing full-length HCV NS5B polymerase sequencing in our clinical microbiology laboratory, we identified atypical HCV sequences, classified as subtype 2l, from 2 patients. HCV-2l NS5B polymerase sequences were detected from 5 and 14 additional patients by screening our laboratory hepatitis virus sequence database and the NCBI GenBank sequence database. Phylogenetic analyses show unambiguously that all HCV-2l sequences are clustered apart from HCV 2 non-l sequences, which compose a second cluster. Mean (±SD) nucleotide identity between near full-length NS5B fragments of subtype 2l was 93.4 ± 0.8% (range: 92.4-95.1). Of note, all HCV-2l sequences obtained in our laboratory and in other centers were from serum samples collected in France. Analysis of the HCV-2l NS5B polymerase amino acid sequences at 30 positions critical for interaction with or resistance to HCV polymerase inhibitors showed specific patterns.

%I Karger Publishers